President Obama promised that the brunt of any financial reckoning will fall mostly only on those making more than $250,000 annually. Under his healthcare plan, the economic agony starts at income levels that fall much lower than that.

The FDA is restricting the speech of private drug firms. This may violate the First Amendment rights of drugs companies.

Scott Gottlieb's testimony on the Independent Payment Advisory Board for the Committee on Ways and Means' subcommittee on health.

The new Obama drug initiative is of a piece with the administration's abiding faith in the virtue of government investment as a trump to private entrepreneurism. At the core of this religion is a faith that that the political allocation of capital leads to better, or at least more "equitable" outcomes.

The Food and Drug Administration's letter to Cheerios typifies the FDA's longstanding discomfort with health claims made on food labels, particularly those touting the medical benefits of certain diets and ingredients.

Two recent experimental drugs demonstrate that new scientific principles are faster becoming superior medicines, but bad government policies threaten to reverse this trend.

The U.S. health system is recognized as the world's leader in clinical innovation, yet millions of Americans do not have health insurance, reducing their access to those life-enhancing and life-saving treatments. AEI has invited twenty academic experts from around the country as well as members of the...

Policies enacted over the last few decades have systematically eroded the ability of manufacturers to earn returns on certain drugs, especially older parenteral drugs sold as generics. We need to reform the policies governing these markets if we're going to lure investment back into these important areas.